Patents by Inventor D. Elshan Nakath G. Ralalage

D. Elshan Nakath G. Ralalage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR
    Publication number: 20220380298
    Abstract: The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
    Type: Application
    Filed: January 13, 2022
    Publication date: December 1, 2022
    Inventors: Matthew Rettig, Michael E. Jung, D. Elshan Nakath G. Ralalage, Jiabin An
  • INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR
    Publication number: 20220177418
    Abstract: The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Inventors: Matthew Rettig, Michael E. Jung, D. Elshan Nakath G. Ralalage, Jiabin An
  • Inhibitors of the N-terminal domain of the androgen receptor
    Patent number: 11261152
    Abstract: The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: March 1, 2022
    Assignees: The Regents of the University of California, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Matthew Rettig, Michael E. Jung, D. Elshan Nakath G. Ralalage, Jiabin An
  • INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR
    Publication number: 20190382335
    Abstract: The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
    Type: Application
    Filed: January 19, 2018
    Publication date: December 19, 2019
    Inventors: Matthew Rettig, Michaei E. Jung, D. Elshan Nakath G. Ralalage, Jiabin An